[Promoting remyelination as a future therapeutic principle in multiple sclerosis?].
Multiple sclerosis (MS), the most common neurological autoimmune disorder diagnosed in young adults, is characterised by the repeated occurrence of demyelinating lesions within the central nervous system (CNS). Promotion of remyelination in the brain and spinal cord constitutes a potential strategy for therapeutic intervention in MS and other demyelinating diseases. Three different principles are known to promote remyelination in the CNS of different animal models: Application of growth factors, transplantation of myelin-forming cells and intravenous immunoglobulin (IVIg) therapy. However, the systemic application of growth factors could be limited by effects on unaffected tissue. For successful transplantation we still have the problem of homologous cells not tolerated by a immunological different organism. Currently the required combination of growth factors needed to cultivate human homologous cells is not known, so that cells suitable for transplantation are still not available. Nevertheless, there is increasing evidence for beneficial effects of IVIg therapy on the promotion of remyelination in humans. In this review we summarise recent findings on the regulation of myelin sheath development and oligodendrocyte differentiation, and discuss the presented strategies in the context of possible clinical application for the therapy of MS.
Pöhlau
D
D
Neurologische Klinik, Ruhr-Universität Bochum am St. Josef Hospital.
Aktas
O
O
Epplen
C
C
Hartung
H P
HP
Hoffmann
V
V
Przuntek
H
H
D000328:Adult; D000818:Animals; D002490:Central Nervous System / Q000503:physiopathology; D006133:Growth Substances / Q000627:therapeutic use; D006801:Humans; D007116:Immunization, Passive; D009103:Multiple Sclerosis / Q000503:physiopathology / Q000628:therapy*; D009185:Myelin Proteins / Q000378:metabolism*; D009836:Oligodendroglia / Q000502:physiology / Q000637:transplantation
D006133:Growth Substances; D009185:Myelin Proteins
Remyelinisierungsförderung als zukünftiges Therapieprinzip der Multiplen Sklerose?